Passage Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PASG research report →
Companywww.passagebio.com
Passage Bio, Inc. , a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.
- CEO
- William Chou
- IPO
- 2020
- Employees
- 60
- HQ
- Philadelphia, PA, US
Price Chart
Valuation
- Market Cap
- $16.68M
- P/E
- -0.44
- P/S
- 0.00
- P/B
- 1.42
- EV/EBITDA
- 0.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -150.88%
- ROIC
- -238.29%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-45,522,000 · 29.71%
- EPS
- $-14.35 · 33.07%
- Op Income
- $-43,151,000
- FCF YoY
- 34.34%
Performance & Tape
- 52W High
- $20.00
- 52W Low
- $3.94
- 50D MA
- $7.04
- 200D MA
- $8.53
- Beta
- 1.38
- Avg Volume
- 80.36K
Get TickerSpark's AI analysis on PASG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 16, 26 | Borthwick Kathleen | other | 15,610 |
| Mar 16, 26 | Chou William | other | 58,000 |
| Jan 8, 26 | Chou William | other | 10,000 |
| Jan 8, 26 | Chou William | other | 10,000 |
| Jan 8, 26 | Chou William | sell | 4,076 |
| Jan 8, 26 | Borthwick Kathleen | other | 5,000 |
| Jan 8, 26 | Borthwick Kathleen | sell | 2,062 |
| Jan 8, 26 | Borthwick Kathleen | other | 5,000 |
| Jan 15, 25 | Borthwick Kathleen | other | 10,000 |
| Jan 15, 25 | Chou William | other | 20,000 |
Our PASG Coverage
We haven't published any research on PASG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PASG Report →